Liver transplantation for HIV-infected patients with end-stage liver disease

Current Opinion in Organ Transplantation

Volumn 7, Issue 2, 2002, Pages 114-123

  Neff, Guy W ^a   Jayaweera, Dushyantha ^a   Tzakis, Andreas G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CYCLOSPORIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; OKT 3; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STEROID; TACROLIMUS; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DISEASE SEVERITY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GRAFT REJECTION; HEALTH ECONOMICS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INCIDENCE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; MEDICAL ETHICS; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; ORGAN DONOR; PATIENT SELECTION; PREVALENCE; SEPSIS; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; VIRUS HEPATITIS; VIRUS LOAD;

EID: 0036046042     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075200-200206000-00002     Document Type: Article

References (111)

1. AIDS across Europe, 1994-98: The EuroSIDA study
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
4. Hepatitis C and HIV infection: Biologic, clinical, and therapeutic implications
5. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers
6. A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy
9. Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981-1986
10. Transplantation in HIV+ patients
11. The acquired immunodeficiency syndrome and transplantation
12. HIV/HCV Coinfection: Clinical and research challenges
13. Human immunodeficiency virus infection in patients with solid-organ transplants: Report of five cases and review
14. Liver transplantation in hemophilia A
15. Human immunodeficiency virus infection transmitted from an organ donor screened for HIV antibody
16. HTLV-III/LAV infection in kidney and liver transplantation
17. Cure of hemophilia A by orthotopic liver transplantation
18. Fatal acute HIV infection with aplastic anaemia, transmitted by liver graft
19. Acute human immunodeficiency virus infection. Antigen detection and seroconversion in immunosuppressed patients
20. Organ transplantation in HIV-positive patients with hemophilia
21. Long-term survival without immunosuppression in HIV-positive liver-graft recipient
22. Outcome of HIV infection in transplant patient on cyclosporin
23. HIV transmission by organ and tissue transplantation
24. Baboon-to-human liver transplantation
25. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1
26. The role of liver transplantation in a severe hemophiliac co-infected with HCV and HIV
27. Liver transplantation for hemophiliacs with hepatitis C cirrhosis
28. Outcome of orthotopic liver transplantation in patients with hemophilia
29. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome
30. Solid organ transplantation in patients with human immunodeficiency syndrome (HIV). A successful case series presentation
31. Liver transplantation in HIV+ patients. The impact of highly active antiretroviral therapy (HAART)
32. Liver Transplantation in Adults Coinfected with HIV
33. Liver Transplantation and HIV-A Case Series of 7 Patients
34. Solid organ transplantation in HIV disease
35. Prevalence of HIV infection in the United States
36. Survival from early, intermediate, and late stages of HIV infection
37. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival
38. Hepatitis C Prevalence in HIV-infected patients: Across sectional analysis of the US Adult Clinical Trials Group
39. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus
40. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
41. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS
42. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections
43. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
44. Hepatitis C virus infection in a human immunodeficiency virus-positive cohort in Hawaii
45. Hepatitis C in the patient with human immunodeficiency virus infection
46. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
47. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C
48. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
49. The spectrum of liver disease in the acquired immunodeficiency syndrome
50. Hepatitis B virus infection in the acquired immunodeficiency syndrome
51. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men
52. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection
53. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection
54. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state
55. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
56. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
57. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
58. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
59. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as low dose hepatitis B immune globulin
60. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
61. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease
62. Immunosuppression in HIV-infected transplant recipients
63. Immunopathogenic mechanisms of HIV infection
64. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506
65. Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A
66. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys
67. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation-data on four cases and review of the literature
68. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: Mechanism for antiviral effects of cyclosporin A
69. HIV infection in cadaveric renal allograft recipients in the North Italy Transplant Program
70. Human immunodeficiency virus (HIV) infection and the kidney
71. AIDS. Politics of premature French claim of cure
72. Inhibition fonctionnelle par la ciclosporine A du recepteur lymphocytaire du virus du sida (HIV)
73. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1
74. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART
75. Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2
76. CD28 costimulation increases CD8+ cell suppression of HIV replication
77. HIV infection facts and hypotheses
78. Cyclosporine
79. Cyclosporine-induced deterioration in patients with AIDS
80. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels
81. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: A concentration-dependent interaction
82. Ribavirin antagonizes the effect of azidothymidine on HIV replication
83. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro
84. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro
85. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus
86. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
87. Coinfections of HIV and chronic hepatitis virus
88. Acetaminophen hepatotoxicity augmented by zidovudine
89. Fulminant hepatic failure in an AIDS patient: Possible zidovudine-induced hepatotoxicity
90. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine
91. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
92. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity
93. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. erratum appears in J Acquir Immune Defic Syndr 2000 Jan 1;23(1):105]
94. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
95. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
96. Transmission of AIDS virus at renal transplantation
97. How does HIV cause AIDS? The homing theory
98. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
99. Visceral abdominal-fat accumulation associated with use of indinavir
100. HAART-Associated Body Habitus and Metabolic Changes
101. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
102. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
103. Psychosocial impact of the lipodystrophy syndrome in HIV infection
104. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
105. Drug-induced hepatitis in the era of HAART
106. La co-infection par les virus de l'hepatite C et de l'immunodeficience humaine a l'ere des multitherapies antiretrovirales
107. Consensus development conference statement: Liver transplantation
108. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
109. Solid organ transplantation in HIV-infected individuals: Obstacles and opportunities
110. Xenotransplantation of hematopoietic cells resistant to HIV as a potential treatment for patients with AIDS